drugset / Trial / NCT01657526
Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' NTHi candidate vaccine in adults, administered for the first time in humans.
Timeline
- Start
- 2012-08-08
- Primary completion
- 2013-11-25
- Completion
- 2013-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK2838500A | Vaccine | — | Intramuscular |
| Subject | GSK2838501A | Vaccine | — | Intramuscular |